Evidence-Based Complementary and Alternative Medicine

Research Article

Kushenin Combined with Adefovir Dipivoxil or Entecavir for Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Table 1

Characteristics of included studies on KS combined with ADV or ETV for the treatment of CHB.


Author, year	Cases C/T	Age (years) range, mean	Gender: male/female	Interventions C/T	Dosage and route of administration	Course of treatment	Adverse events	Outcome measures

Li et al., 2020	90/90	22–42, 32.3 ± 8.7	127/53	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	6 months	NR	①③④

Xia et al., 2020	51/51	C: 18–63, 48 ± 9 T: 20–65, 48 ± 9	C: 29/22 T: 27/24	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	1 year	√	①④⑦

Zhao and Li, 2019	62/62	C: 19–57, 32.56 ± 7.38 T: 21–58, 31.43 ± 6.79	C: 44/18 T: 45/17	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	√	①④⑤⑥⑦

Wang et al., 2017	50/50	32.34 ± 7.44	C: 30/20 T: 32/18	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	NR	①②⑤⑥⑦

Kang, 2016	40/40	47.5 ± 4.7	43/37	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	0	①②③

Zhang et al., 2016	104/112	C: 21–57 T: 22–58	C: 57/47 T: 63/49	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	NR	①②③④⑤⑦

Sun, 2016	53/53	39.5 ± 4.7	79/27	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	12 months	√	①②③④⑤⑦

Fang et al., 2014	30/60	16–65	NR	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	24 months	√	①②③

Qian and Hu, 2014	48/44	C: 35.13 ± 7.45 T: 34.27 ± 6.23	C: 41/7 T: 35/9	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	1 year	√	①②③④⑤⑦

Ren et al., 2014	48/52	47.5 ± 4.8	53/47	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	√	①②③

Wu, 2013	42/40	C: 36.6 ± 8.6 T: 36.9 ± 6.9	C: 24/18 T: 23/17	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.3 g/time, po, tid	12 months	0	①③④

Xu and Liang, 2013	40/40	16–65	NR	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	√	①②③

Zhang, 2013	38/38	46.8 ± 3.9	39/37	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	√	①③④

Gong and Sheng, 2013	50/52	C: 35.1 ± 4.5 T: 32.2 ± 5.6	C: 41/9 T: 42/10	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	1 year	√	①②③④⑤⑦

Zhang et al., 2013	50/59	C: 31.5 (26, 37) T: 33.0 (28, 44)	C: 29/21 T: 38/21	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.4 g/time, po, tid	48 weeks	√	①②③④

Shen, 2013	36/34	16–48	42/28	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	NR	①③④

Zhao, 2013	104/104	C: 32.8 ± 4.7 T: 31.3 ± 4.6	C: 68/36 T: 72/32	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	1 year	NR	①②③④

Yin, 2013	50/50	C: 42.8 ± 8.1 T: 44.1 ± 9.2	C: 30/20 T: 29/21	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	12 months	√	①②③④⑤⑦

Hu and Sun, 2012	52/54	C: 30.63 ± 10.53 T: 29.48 ± 8.27	C: 34/18 T: 38/16	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	52 weeks	√	①②③④⑤

Lv et al., 2011	50/54	C: 33.5 T: 32.5	C: 39/11 T: 42/12	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.3 g/time, po, tid	9 months	0	①②③⑥

Yan et al., 2011	62/70	C: 32 ± 6 T: 32 ± 6	C: 49/13 T: 52/18	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.15 g/time, po, tid	52 weeks	√	①④

Yang et al., 2011	40/40	22–48 (37)	48/32	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	12 months	√	①④⑦

Zhang, 2011	34/30	C: 35 T: 33	C: 23/11 T: 18/12	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	3 years	√	①②③④

Cheng 2011	44/48	34 ± 5.8	63/29	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	NR	①②③④

Yin and Ni, 2011	30/30	NR	NR	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	NR	①②④

Shen, 2010	34/38	16–65	42/30	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	12 months	NR	①②③④⑥

Zhang and Hu, 2010	32/46	C: 31.3 ± 7.9 T: 32.5 ± 8.3	C: 22/10 T : 32/14	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	12 months	√	①③④

Zhou, 2010	115/115	42.5 ± 4.8	168/62	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.3 g/time, po, tid	48 weeks	√	①②③④⑥

Shao and Zhang, 2010	44/48	34 ± 5.8	63/29	C: ETV T: ETV + KS	ETV: 0.5 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	NR	①②③④

Zhang, 2009	40/40	18–55 (38)	60/20	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	1 year	NR	①②③

Wei et al., 2008	39/33	15–65	43/29	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	48 weeks	NR	①②③④

Liu et al., 2007	30/34	16–65	NR	C: ADV T: ADV + KS	ADV: 10 mg/d, po, qd KS: 0.2 g/time, po, tid	12 months	0	①②③④⑥

① Undetectable serum HBV-DNA rate, ② loss of serum HBeAg rate, ③ ALT normalization rate, ④ HBeAg seroconversion rate, ⑤ serum HBV-DNA level, ⑥ loss of serum HBsAg rate, and ⑦ serum ALT levels. 0, reported with no cases. Kushenin: KS; ADV: adefovir dipivoxil; ETV: entecavir; CHB: chronic hepatitis B; NR: not reported; C: control groups; T: trial groups; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase.